Short-term follow-up of cryopreserved allograft valves and valved conduits from the CryoLife clinical registry
CryoLife, a laboratory which specializes in the cryopreservation of human tissues for transplant, first started preserving valves in Autumn 1984. The hearts which arrive at CryoLife are currently procured by 144 independent organ and tissue procurement agencies in the United States, Canada and West Germany. This procured tissue is preserved by CryoLife as a service to those agencies or doctors to whom the tissue has been assigned. In order to assure consistent quality control, all agencies follow the guidelines printed in the CryoLife (3) heart valve procurement protocol. The protocol provides information for screening for infectious diseases and diseases of the heart which would render the tissue less than ideal. For instance, when the required serum sample is returned by the procuring group, tests are performed for HIV (AIDS), hepatitis, syphilis and CMV (cytomegalovirus). These internal tests are compared with pretest data which accompanies the organ and are used as a double check to confirm that the possibility of transmission of these diseases is eliminated. The donor form also contains a detailed medical history of the donor, which helps eliminate donors of questionable standards or with a history of cardiac complications. The protocol also contains the precise details for the surgical extraction of the heart so that uniformity amongst participating centres is maintained.
KeywordsAortic Valve Heart Valve Valve Conduit Allograft Valve Ventricular Outflow Tract Reconstruction
Unable to display preview. Download preview PDF.
- 2.Broekbank KGM, Bank HL (1987) Measurement of post cryopreservation viability. J Cardiac Surg Suppl II: 145Google Scholar
- 3.CryoLife Inc. Clinical Program 101 allograft heart valves (1987) CryoLife Inc., Marietta, Georgia, U.S.A.Google Scholar
- 4.Kirklin JW, Barratt-Boyes BG (1986) Cardiac surgery. John Wiley, New York. Chapter 12: Aortic valve disease, p 373–429Google Scholar
- 6.O’Brien MF, Stafford G, Gardner M, Phlner P, McGiffm D, Johnston N, Brosnan A, Duffy P (1987) The viable cryopreserved allograft aortic valve. J Cardiac Surg Suppl 2: 153–157Google Scholar
- 7.Ross D, Martelli M (1979) Allograft and autograft valves used for aortic valve replacement, In: Ionescu M (ed) Tissue heart valves. Butterworth, London, pp 127–172Google Scholar
- 11.Yankah AC, Randzio G, Wottge HU, Bernard A (1985) Factors influencing endothelial cell viability during procurement and preservation of valve allografts. In: Theide A, Deltz E, En-gemann R, Hamelmann H (eds) Microsurgical models in rats for transplantation research. Springer-Verlag, Berlin, p 107CrossRefGoogle Scholar
- 12.Yankah AC, Wottge HU, Muller-Hermelink HK, Feller AC, Large P, Wessel U, Dreyer H, Bern-hard A, Muller-Ruchholtz W (1987) Transplantation of aortic and pulmonary allografts, enhanced viability of endothelial cells by cryopreservation, importance of histocompatibility. J Cardiac Surg Suppl 2: 209–220Google Scholar